BioSpace News Archive

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that it has received a Notice of Allowance for an additional composition of matter and method of use patent from the US Patent and Trademark Office (USPTO)

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a research collaboration agreement with the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC) to advance characterization and development of human monoclonal antibodies (mAbs) against coronaviruses, including SARS-CoV-2, the virus that causes the disease COVID-19.

Progressive Care Inc., a personalized healthcare services and technology company, is proud to announce the launch of its newly redesigned website.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that it will release its financial results for the twelve month period ended December 31, 2019 before the market opens on Tuesday, March 31, 2020 and host a conference call to discuss the results at 8:00 a.m. ET.

As concerns about containment of coronavirus (COVID-19) continue to evolve, the mental health community overall is working hard to accommodate care needs.

Oakrum Pharma, LLC (“Oakrum”) announced today the launch and commercial distribution of pyrimethamine 25mg tablets in the United States.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced U.S. Food and Drug Administration (“FDA”) clearance of the Company’s Special 510(k) Premarket Notification regarding its Generation II Rapid Acoustic Pulse (“RAP”) device.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of the Company’s recent progress and key clinical readouts anticipated in 2020.

To help the fightback against the current Coronavirus outbreak, labs across the globe at the forefront of the scientific response have been sharing genomes and protein structures in open access databases.

Sony Corporation (“Sony”) today announced the launch of KIRAVIA1* Dyes™, a new family of fluorescent dyes, for use in reagents for a wide range of life science applications. Fluorescent reagents are used to study the characteristics of tissues and cells in the life sciences fields, such as immunology and regenerative medicine